Key Highlights
- Novo Nordisk introduced subscription-based pricing for Wegovy, featuring 3-, 6-, and 12-month commitment options for cash-paying customers
- Monthly costs for injections start at $329 (3-month plan) and drop to $249 (12-month plan), representing up to 29% savings from the regular $349 price point
- Oral Wegovy subscriptions are priced between $249–$289 monthly, compared to the standard $299 cost
- Available now via telehealth providers Ro, WeightWatchers, and LifeMD, with Hims & Hers and Sesame joining shortly
- Market dynamics show Eli Lilly commanding approximately 60% of the U.S. branded GLP-1 segment versus Novo’s roughly 39%
Novo Nordisk is making a bold move to capture more of the self-funded obesity treatment market by rolling out subscription-based pricing for Wegovy, positioning itself more aggressively against competitor Eli Lilly in a rapidly evolving landscape.
The Copenhagen-based pharmaceutical giant unveiled the initiative Tuesday, enabling qualifying self-pay customers to secure predictable monthly costs through tiered subscription periods. Extended commitments translate directly into greater savings.
Patients choosing the injectable version of Wegovy will pay $329 monthly for a 3-month subscription, $299 for a 6-month term, and $249 for an annual commitment. These rates compare favorably against the baseline $349 monthly cost — delivering discounts reaching 29%.
The oral Wegovy formulation, which entered the U.S. market this past January, mirrors this tiered approach: $289, $269, or $249 monthly versus the conventional $299 price tag. Annual savings potential reaches $600 for pill users and $1,200 for injection patients under the maximum-length subscription.
Pricing remains consistent regardless of dose adjustments, eliminating a common source of frustration for patients paying out of pocket for GLP-1 medications.
Access begins immediately via Ro, WeightWatchers, and LifeMD platforms. Additional partners including Hims & Hers and Sesame will join the network imminently. Novo’s proprietary NovoCare pharmacy doesn’t currently offer the program, though future expansion remains possible.
Strategic Rationale Behind the Launch
The rollout arrives at a critical juncture for Novo. Market data reveals Eli Lilly dominates approximately 60% of the U.S. branded GLP-1 sector, leaving Novo with roughly 39%. Lilly established its direct-to-consumer presence earlier and has watched its Zepbound product surpass Wegovy in prescription velocity.
Novo has undertaken significant internal restructuring — replacing its chief executive, implementing workforce reductions, and appointing new leadership for its American operations. This subscription offering represents the latest component of that strategic pivot.
The pill formulation has successfully attracted patients new to GLP-1 therapy, making the pre-approval period before Lilly’s competing oral medication particularly valuable. Lilly’s oral obesity treatment currently awaits FDA clearance, with a potential decision anticipated in April.
Industry observers have noted Novo’s vulnerability in potential pricing competition, particularly after slashing Wegovy injection’s standard cash price from $499 to $349 last November — a substantial 30% reduction.
Competitive Pricing Landscape
Lilly positions its Zepbound self-pay rates at $299/month for the 2.5mg dosage, $399 for 5mg, and $449 for higher-strength options through its “Self Pay Journey Program.”
Patient retention represents a critical challenge the subscription model addresses directly. Research published in 2025 indicated approximately 65% of obesity patients discontinue GLP-1 therapy within twelve months, frequently citing financial unpredictability and adverse reactions.
Ed Cinca, Novo’s marketing and patient solutions executive, emphasized that subscribers maintain flexibility to discontinue their plans during the active subscription period.
The 4mg Wegovy pill dosage, currently available at $149/month, will increase to $199 beginning September. The newly approved 7.2mg strength will be integrated into subscription offerings at an unspecified future date.
